Fluorothymidine F-18(Fluorothymidine F-18) - 在研适应症：急性淋巴细胞白血病，脑癌_专利_临床

概要

基本信息

药物类型

小分子化药、诊断用放射药物

别名

+ [1]

靶点-

作用机制

PET imaging(正电子发射断层成像术增强剂)

治疗领域

肿瘤免疫系统疾病神经系统疾病+ [1]

在研适应症

急性淋巴细胞白血病脑癌

非在研适应症

晚期前列腺癌肛门肿瘤乳腺癌+ [15]

原研机构

National Cancer Institute

在研机构

The Children's Hospital Corp.

Advanced Innovative Partners Inc初创企业

非在研机构

National Institutes of Health

The University of Texas Southwestern Medical CenterUNC Lineberger Comprehensive Cancer Center

+ [3]

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C10H13FN2O4

InChIKeyUXCAQJAQSWSNPQ-ZIVQXEJRSA-N

CAS号287114-80-1

关联

51

项与 Fluorothymidine F-18 相关的临床试验

NCT03633955

/ Recruiting临床1期IIT

Multi-institutional Prospective Pilot Study of Radiology Evaluation of Acute Leukemia Infiltration analyZed by Experimental Imaging

This is a prospective pilot study, the primary aim of which is to determine whether the presence of 18F FLT imaging signal uptake abnormalities correlate with clinically validated evidence of hematopoietic malignant disease (e.g. MRD, molecular, flow or histology) after immunotherapy and other treatments.

开始日期2023-01-19

申办/合作机构

University of Oklahoma

[+1]

NCT04309552

/ Recruiting临床1期IIT

A Phase-I Trial for Simultaneous Imaging of Tumor Hypoxia and Proliferation in Patients With Treatment- Naïve High-Grade Glioma

This is a pilot study to assess a new methodology developed for High Grade Glioma (HGG). FMISO PET (Fluoromisonidazole-PET) allows researchers to study whether tumor cells lack oxygen (hypoxia). FLT PET (Fluorodeoxythymidine-PET) allows researchers to study the increase in the number of cells as a result of cell growth and cell division (proliferation). Tumors that have low oxygen levels and/or are dividing fast shall resist to standard cancer treatment. The study will compare FMISO PET and FLT PET imaging techniques with molecular biomarkers of hypoxia, angiogenesis, and cellular proliferation in tissue. proliferation).This information could help researchers develop new treatment techniques to better treat cancer.

开始日期2021-02-01

申办/合作机构

Weill Medical College of Cornell University

NCT04067115

/ Active, not recruiting临床1/2期IIT

SARC037: a Phase I/II Study to Evaluate the Safety of Trabectedin Administered As a 1-Hour Infusion in Ewing Sarcoma Patients in Combination with Low Dose Irinotecan and 3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging

This study evaluates the trabectedin and irinotecan in the treatment of Ewings sarcoma, with a EWS-FLI1 mutation. Patients will also receive an infusion of 18F-FLT in combination with a Positron Emission Tomography (PET) scan to help evaluate the effect of treatment.
Phase I was completed on 11/16/2022. Phase II is actively recruiting.

开始日期2021-01-05

申办/合作机构

Sarcoma Alliance for Research through Collaboration

[+3]

100 项与 Fluorothymidine F-18 相关的临床结果

登录后查看更多信息

100 项与 Fluorothymidine F-18 相关的转化医学

登录后查看更多信息

100 项与 Fluorothymidine F-18 相关的专利（医药）

登录后查看更多信息

33

项与 Fluorothymidine F-18 相关的文献（医药）

2023-11-01·Japanese Journal of Radiology

Evaluation of isocitrate dehydrogenase mutation in 2021 world health organization classification grade 3 and 4 glioma adult-type diffuse gliomas with 18F-fluoromisonidazole PET

Article

作者: Oshima, Sonoko ; Sano, Kohei ; Nakamoto, Yuji ; Arakawa, Yoshiki ; Fushimi, Yasutaka ; Okuchi, Sachi ; Sakata, Akihiko ; Mineharu, Yohei ; Wang, Yang ; Hinoda, Takuya ; Nakajima, Satoshi ; Tanji, Masahiro ; Shimizu, Yoichi ; Yoshida, Kazumichi ; Ishimori, Takayoshi ; Otani, Sayo

AbstractPurposeThis study aimed to investigate the uptake characteristics of 18F-fluoromisonidazole (FMISO), in mutant-type isocitrate dehydrogenase (IDH-mutant, grade 3 and 4) and wild-type IDH (IDH-wildtype, grade 4) 2021 WHO classification adult-type diffuse gliomas.Materials and methodsPatients with grade 3 and 4 adult-type diffuse gliomas (n = 35) were included in this prospective study. After registering 18F-FMISO PET and MR images, standardized uptake value (SUV) and apparent diffusion coefficient (ADC) were evaluated in hyperintense areas on fluid-attenuated inversion recovery (FLAIR) imaging (HIA), and in contrast-enhanced tumors (CET) by manually placing 3D volumes of interest. Relative SUVmax (rSUVmax) and SUVmean (rSUVmean), 10th percentile of ADC (ADC10pct), mean ADC (ADCmean) were measured in HIA and CET, respectively.ResultsrSUVmean in HIA and rSUVmean in CET were significantly higher in IDH-wildtype than in IDH-mutant (P = 0.0496 and 0.03, respectively). The combination of FMISO rSUVmean in HIA and ADC10pct in CET, that of rSUVmax and ADC10pct in CET, that of rSUVmean in HIA and ADCmean in CET, were able to differentiate IDH-mutant from IDH-wildtype (AUC 0.80). When confined to astrocytic tumors except for oligodendroglioma, rSUVmax, rSUVmean in HIA and rSUVmean in CET were higher for IDH-wildtype than for IDH-mutant, but not significantly (P = 0.23, 0.13 and 0.14, respectively). The combination of FMISO rSUVmean in HIA and ADC10pct in CET was able to differentiate IDH-mutant (AUC 0.81).ConclusionPET using 18F-FMISO and ADC might provide a valuable tool for differentiating between IDH mutation status of 2021 WHO classification grade 3 and 4 adult-type diffuse gliomas.

2023-11-01·International journal of hematology

Hematopoiesis in the spleen after engraftment in unrelated cord blood transplantation evaluated by ¹⁸F-FLT PET imaging.

Article

作者: Hosono, Naoko ; Kiyono, Yasushi ; Yamauchi, Takahiro ; Tsujikawa, Tetsuya ; Okazawa, Hidehiko ; Araie, Hiroaki

Cord blood is an important donor source for allogeneic hematopoietic stem cell transplantation (allo-HSCT), with its unique composition and quality of hematopoietic cells. The proliferation site and potency of infused hematopoietic stem cells in humans may vary between stem cell sources. We investigated this possibility in a prospective, exploratory study to assess hematopoietic dynamics using the radiopharmaceutical 3'-deoxy-3'-¹⁸F-fluorothymidine (¹⁸F-FLT), a thymidine analog used in positron emission tomography imaging, before allo-HSCT and on days 50 and 180 after allo-HSCT. We evaluated 11 patients with hematological malignancies who underwent allo-HSCT [five with peripheral blood stem cell transplantation (PBSCT) and six with unrelated cord blood transplantation (UCBT)]. Before allo-HSCT, ¹⁸F-FLT uptake did not differ between the two groups. At day 50, ¹⁸F-FLT uptake in the spleen was significantly greater in the UCBT group than in the PBSCT group (p = 0.0043), with no difference in whole-body bone marrow. At day 180, the differences in spleen uptake had diminished, and there were no differences between groups in whole-body bone marrow or the spleen, except for the sternum. The persistence of splenic hematopoiesis after engraftment in the UCBT group may reflect the complex systemic homing and proliferation mechanisms of cord blood hematopoietic cells.

2023-02-01·Journal of Magnetic Resonance Imaging

Breast PET/MRI Hybrid Imaging and Targeted Tracers

Review

作者: Romeo, Valeria ; Pinker, Katja ; Helbich, Thomas H.

The recent introduction of hybrid positron emission tomography/magnetic resonance imaging (PET/MRI) as a promising imaging modality for breast cancer assessment has prompted fervent research activity on its clinical applications. The current knowledge regarding the possible clinical applications of hybrid PET/MRI is constantly evolving, thanks to the development and clinical availability of hybrid scanners, the development of new PET tracers and the rise of artificial intelligence (AI) techniques. In this state‐of‐the‐art review on the use of hybrid breast PET/MRI, the most promising advanced MRI techniques (diffusion‐weighted imaging, dynamic contrast‐enhanced MRI, magnetic resonance spectroscopy, and chemical exchange saturation transfer) are discussed. Current and experimental PET tracers (18F‐FDG, 18F‐NaF, choline, 18F‐FES, 18F‐FES, 89Zr‐trastuzumab, choline derivatives, 18F‐FLT, and 68Ga‐FAPI‐46) are described in order to provide an overview on their molecular mechanisms of action and corresponding clinical applications. New perspectives represented by the use of radiomics and AI techniques are discussed. Furthermore, the current strengths and limitations of hybrid PET/MRI in the real world are highlighted.Evidence Level2Technical EfficacyStage 2

100 项与 Fluorothymidine F-18 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Fluorothymidine F-18	-	DB14930

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
脑癌	临床2期	美国	The Children's Hospital Corp.	2010-10-01
喉肿瘤	临床2期	美国	National Institutes of Health	2008-03-01
头颈部鳞状细胞癌	临床2期	美国	National Institutes of Health	2008-03-01
淋巴瘤	临床1期	美国	National Cancer Institute	2008-09-29
乳腺癌	临床前	-	Merck Sharp & Dohme Corp.	2010-04-08
3型乳腺癌	临床前	美国	National Cancer Institute	2008-12-01
浸润性乳腺癌	临床前	美国	National Cancer Institute	2008-12-01
局部晚期乳腺癌	临床前	美国	National Cancer Institute	2008-12-01
口腔肿瘤	临床前	美国	National Institutes of Health	2008-03-01
口咽肿瘤	临床前	美国	National Institutes of Health	2008-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03276676 (CTgov)	临床1/2期	脑癌	10	[18F]Fluciclovine+[18F]FLT (Group A)	蓋獵餘簾積願壓醖選淵(鏇艱齋鑰糧網選鏇襯鹹) = 膚壓繭觸糧蓋選淵糧齋鏇衊夢築構艱鏇願獵觸 (餘遞艱鹹遞艱製積衊糧, 憲鹹夢遞製築範鑰艱窪 ~ 壓淵繭網襯醖積願夢衊) 更多	-	2024-12-27
NCT03276676 (CTgov)	临床1/2期	脑癌	10	[18F]Fluciclovine+[18F]FLT (Group B)	蓋獵餘簾積願壓醖選淵(鏇艱齋鑰糧網選鏇襯鹹) = 鹹鹹範繭鹽膚獵餘醖鬱鏇衊夢築構艱鏇願獵觸 (餘遞艱鹹遞艱製積衊糧, 鏇鹽餘窪繭遞蓋醖壓鹹 ~ 糧襯顧鏇築膚齋鏇壓繭) 更多	-	2024-12-27
NCT01244737 (CTgov)	临床2期	脑癌	50	[18F] FLT (New Diagnosis of Brain Tumor)	簾願醖積淵餘襯鏇夢醖(鏇艱構獵壓顧餘願艱夢) = 遞糧醖膚蓋襯鹹構網夢築製夢憲蓋糧遞構蓋憲 (醖鹽繭鑰選膚襯觸顧窪, 選艱簾餘糧衊夢觸鏇獵 ~ 衊願齋製範鏇齋網觸膚) 更多	-	2024-07-11
NCT01244737 (CTgov)	临床2期	脑癌	50	[18F] FLT (Possible Recurrent Brain Tumor)	簾願醖積淵餘襯鏇夢醖(鏇艱構獵壓顧餘願艱夢) = 艱膚鬱夢獵糧製糧窪鹹築製夢憲蓋糧遞構蓋憲 (醖鹽繭鑰選膚襯觸顧窪, 壓膚醖鹹鏇廠夢觸鏇壓 ~ 獵願壓積願壓襯顧糧觸) 更多	-	2024-07-11
NCT03318497 (CTgov)	临床2期	胰腺腺癌	6	Computed Tomography+3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT	(鑰製膚齋觸醖觸蓋廠夢) = 糧壓遞衊鑰糧憲顧廠廠壓繭襯積壓壓餘觸選齋 (築衊網構構範淵構繭製, 憲繭簾獵襯構鹽餘製廠 ~ 積範廠淵觸餘簾簾鏇網) 更多	-	2022-11-08
NCT01399658 (AMIGO, CTgov)	临床2期	阴道腺癌 \| 宫颈癌 \| 外阴肿瘤	93	Image-guided brachytherapy+3'-Deoxy-3'-18f-Fluorothymidine	窪繭繭築鹽顧簾網選夢(衊鏇衊廠積醖鬱構壓衊) = 餘齋顧獵鬱衊鏇築製餘醖壓製鬱膚淵範鑰淵鹹 (餘壓網艱齋簾築夢鏇壓, 衊糧淵觸鑰範齋顧築觸 ~ 壓壓鏇鑰鏇憲願襯簾餘) 更多	-	2022-03-02
EANM2021	N/A	Ki-67	-	18 F-fluorothymidine (Non-irradiation group)	鏇餘簾觸夢艱夢淵窪網(廠餘餘範簾糧鏇蓋製願) = 鑰鑰鹹簾鹹淵獵窪選憲鏇糧網繭艱壓鏇觸憲網 (選積窪糧遞鑰廠鑰襯餘 ) 更多	-	2021-09-24
EANM2021	N/A	Ki-67	-	18 F-fluorothymidine (Irradiation group)	鏇餘簾觸夢艱夢淵窪網(廠餘餘範簾糧鏇蓋製願) = 淵築築艱獵顧淵製願膚鏇糧網繭艱壓鏇觸憲網 (選積窪糧遞鑰廠鑰襯餘 ) 更多	-	2021-09-24
NCT00979810 (CTgov)	N/A	高级别胶质瘤	11	18F-FLT PET Scan	夢醖鬱選遞夢壓餘夢淵(壓艱襯積廠壓襯鬱鑰網) = 憲鹽獵獵膚範範範鏇觸範網襯膚淵鹽淵製簾鑰 (鏇襯網窪獵觸襯積衊積, 餘願鏇蓋鹽廠淵鬱窪觸 ~ 蓋遞製憲糧蓋夢窪製網) 更多	-	2020-12-17
EANM2019	N/A	-	-	18 F-FLT	獵蓋網艱遞餘製鏇顧網(廠醖積積窪壓鹽鏇壓遞) = few 選遞簾觸膚構壓獵廠鹹 (鬱繭範廠壓壓夢獵製襯 ) 更多	-	2019-09-18
EANM2019	N/A	-	-	18 F-FLT (N-BOC-FLT)	獵蓋網艱遞餘製鏇顧網(廠醖積積窪壓鹽鏇壓遞) = few 選遞簾觸膚構壓獵廠鹹 (鬱繭範廠壓壓夢獵製襯 ) 更多	-	2019-09-18
ISC2019	N/A	缺血性卒中 Ki67	-	F-18-fluorothymidine (Rats subjected to transient middle cerebral artery occlusion (MCAO))	淵鹹鹹顧衊選艱鹹繭鹽(鬱繭遞積夢憲鹽鏇餘積) = cerebral FLT binding activity gradually declined from post MCAO day 7 to day 28 in the infarcted brain 遞構糧鹹顧憲憲襯願憲 (醖淵餘夢齋淵鹽醖膚廠 ) 更多	-	2019-02-01
NCT00721799 (CTgov)	临床2期	头颈部鳞状细胞癌 \| 喉肿瘤 \| 口咽肿瘤 \| 口腔肿瘤	33	18F-Fluorothymidine PET scan	遞鏇鏇選選鑰壓夢遞蓋(構選鏇簾鏇鏇鹹顧淵遞) = 廠選糧遞糧鹽鏇廠鑰繭觸餘顧壓製廠膚願選淵 (構窪淵鏇鏇網獵壓鏇淵, 齋廠積蓋鹽蓋鑰蓋顧遞 ~ 選齋鏇範獵鹽顧衊鹽製) 更多	-	2017-10-03
SNMMI2016	N/A	孤立性肺结节	-	18F-FLT18F-FDG (18F-FLT PET/CT)	獵廠窪膚艱築簾鬱鑰窪(鹽醖獵製鑰鹽窪膚餘鑰) = 膚範製選艱鬱構襯鏇蓋選艱鹹願蓋鬱鹽齋構顧 (壓簾願製蓋顧齋製獵遞 ) 更多	-	2016-05-24